Dysautonomias in parkinson’s disease: Cardiovascular changes and autonomic modulation in conscious rats after infusion of bilateral 6-OHDA in substantia nigra

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 308, Issue 3, 2015, Pages H250-H257

  Ariza, D ^a   Sisdeli, L ^a   Crestani, C C ^b   Fazan, R ^c   Martins Pinge, M C ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Baroreflex; Dopamine; Parasympathetic; Prazosin; Spectral analysis; Sympathetic

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; OXIDOPAMINE; ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; CORPUS STRIATUM; DYSAUTONOMIA; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PARKINSON DISEASE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; ADRENERGIC SYSTEM; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DRUG EFFECTS; PATHOPHYSIOLOGY; WISTAR RAT;

ADRENERGIC ANTAGONISTS; ANIMALS; BAROREFLEX; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; HEART RATE; MALE; MUSCARINIC ANTAGONISTS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SYMPATHETIC NERVOUS SYSTEM;

EID: 84943589424     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00406.2014     Document Type: Article

References (43)

1. Anonymous. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysi-ology. Circulation 93: 1043–1065, 1996.
2. Adhiyaman V, Hobson P, Meara RJ. Central and peripheral autonomic integrity in Parkinson’s disease. Age Ageing 37: 578–581, 2008.
3. Ariza D, Lima MM, Moreira CG, Dombrowski PA, Avila TV, Alle-mand A, Mendes DA, Da Cunha C, Vital MA. Intranigral LPS administration produces dopamine, glutathione but not behavioral impairment in comparison to MPTP and 6-OHDA neurotoxin models of Parkinson’s disease. Neurochem Res 35: 1620–1627, 2010.
4. Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costantino G, Pezzoli G, Porta A, Malliani A, Furlan R. Early abnormalities of vascular and cardiac autonomic control in Parkinson’s disease without orthostatic hypotension. Hypertension 49: 120–126, 2007.
5. Boulamery A, Simon N, Vidal J, Bruguerolle B. Effects of L-Dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study. Chronobiol Int 27: 251–264, 2010.
6. Buob A, Winter H, Kindermann M, Becker G, Moller JC, Oertel WH, Bohm M. Parasympathetic but not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. Clin Res Cardiol 99: 701–706, 2010.
7. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 5: 235–245, 2006.
8. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8: 464–474, 2009.
9. Chiaravalloti A, Stefani A, Di Biagio D, Pierantozzi M, Tavolozza M, Di Pietro B, Stanzione P, Schillaci O. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med 27: 444–451, 2013.
10. da Cunha NV, Pinge-Filho P, Panis C, Silva BR, Pernomian L, Grando MD, Cecchini R, Bendhack LM, Martins-Pinge MC. Decreased endothelial nitric oxide, systemic oxidative stress, and increased sympathetic modulation contribute to hypertension in obese rats. Am J Physiol Heart Circ Physiol 306: H1472–H1480, 2014.
11. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 39: 889–909, 2003.
12. Dutra SG, Pereira AP, Tezini GC, Mazon JH, Martins-Pinge MC, Souza HC. Cardiac autonomic modulation is determined by gender and is independent of aerobic physical capacity in healthy subjects. PloS One 8: e77092, 2013.
13. Duty S, Jenner P. Animal models of Parkinson’s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol 164: 1357–1391, 2011.
14. Fazan Junior R, Castania JA, Ballejo G, Salgado MC, Salgado HC. Influence of sympathetic blockade on the acute hypertensive response to aortic constriction. Am J Physiol Heart Circ Physiol 273: H2648–H2651, 1997.
15. Goldstein DS. Cardiac denervation in patients with Parkinson disease. Cleve Clin J Med 74: Suppl 1: S91–S94, 2007.
16. Goldstein DS. Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2: 669–676, 2003.
17. Goldstein DS, Holmes CS, Dendi R, Bruce SR, Li ST. Orthostatic hypotension from sympathetic denervation in Parkinson’s disease. Neurology 58: 1247–1255, 2002.
18. Jain S. Multi-organ autonomic dysfunction in Parkinson disease. Parkin-sonism Relat Disord 17: 77–83, 2011.
19. Jost WH. Autonomic dysfunctions in idiopathic Parkinson’s disease. J Neurol 250 Suppl 1: I28–I30, 2003.
20. Karlen-Amarante M, da Cunha NV, de Andrade O, de Souza HC, Martins-Pinge MC. Altered baroreflex and autonomic modulation in monosodium glutamate-induced hyperadipose rats. Metabolism 61: 1435– 1442, 2012.
21. Khedr EM, El Fetoh NA, Khalifa H, Ahmed MA, El Beh KM. Prevalence of nonmotor features in a cohort of Parkinson’s disease patients. Clin Neurol Neurosurg 115: 673–677, 2013.
22. Kirouac GJ, Ciriello J. Cardiovascular depressor responses to stimulation of substantia nigra and ventral tegmental area. Am J Physiol Heart Circ Physiol 273: H2549–H2557, 1997.
23. Lipp A, Sandroni P, Low PA. Systemic postganglionic adrenergic studies do not distinguish Parkinson’s disease from multiple system atrophy. J Neurol Sci 281: 15–19, 2009.
24. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 18 Suppl 1: 8–13, 2008.
25. Lu SF, Young HJ, Lin MT. Nigrostriatal dopamine system mediates baroreflex sensitivity in rats. Neurosci Lett 190: 17–20, 1995.
26. Nicaretta DH, Pereira JS, Pimentel ML. Autonomic disorders in Parkinson’s disease. Rev Assoc Med Bras 44: 120–122, 1998.
27. Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H. Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease. Brain Pathol 17: 24–30, 2007.
28. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. San Diego, CA: Elsevier, 1998.
29. Przedborski S. Pathogenesis of nigral cell death in Parkinson’s disease. Parkinsonism Relat Disord 11: Suppl 1: S3–S7, 2005.
30. Rahman F, Goldstein DS. Quantitative indices of baroreflex-sympatho-neural function: application to patients with chronic autonomic failure. Clin Auton Res 24: 103–110, 2014.
31. Sakata M, Sei H, Toida K, Fujihara H, Urushihara R, Morita Y. Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation. Brain Res 928: 194–201, 2002.
32. Schwartz CE, Medow MS, Messer Z, Stewart JM. Spontaneous fluctuation indices of the cardiovagal baroreflex accurately measure the baroreflex sensitivity at the operating point during upright tilt. Am J Physiol Regul Integr Comp Physiol 304: R1107–R1113, 2013.
33. Sharabi Y, Goldstein DS. Mechanisms of orthostatic hypotension and supine hypertension in Parkinson disease. J Neurol Sci 310: 123–128, 2011.
34. Singer C, Weiner WJ, Sanchez-Ramos JR. Autonomic dysfunction in men with Parkinson’s disease. Eur Neurol 32: 134–140, 1992.
35. Sorensen GL, Mehlsen J, Jennum P. Reduced sympathetic activity in idiopathic rapid-eye-movement sleep behavior disorder and Parkinson’s disease. Auton Neurosci 179: 138–141, 2013.
36. Souza HC, Martins-Pinge MC, Dias da Silva VJ, Borghi-Silva A, Gastaldi AC, Blanco JH, Tezini GC. Heart rate and arterial pressure variability in the experimental renovascular hypertension model in rats. Auton Neurosci 139: 38–45, 2008.
37. Tezini GC, Dias DP, Souza HC. Aerobic physical training has little effect on cardiovascular autonomic control in aging rats subjected to early menopause. Exp Gerontol 48: 147–153, 2013.
38. Tieu K. A guide to neurotoxic animal models of Parkinson’s disease. Cold Spring Harb Perspect Med 1: a009316, 2011.
39. Valko PO, Hauser S, Werth E, Waldvogel D, Baumann CR. Heart rate variability in patients with idiopathic Parkinson’s disease with and without obstructive sleep apnea syndrome. Parkinsonism Relat Disord 18: 525– 531, 2012.
40. Vanderlei LC, Pastre CM, Hoshi RA, Carvalho TD, Godoy MF. Basic notions of heart rate variability and its clinical applicability. Rev Bras Cir Cardiovasc 24: 205–217, 2009.
41. Wolters E. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord 15, Suppl 3:, 2009.
42. Yu JG, Wu J, Shen FM, Cai GJ, Liu JG, Su DF. Arterial baroreflex dysfunction fails to mimic Parkinson’s disease in rats. J Pharmacol Sci 108: 56–62, 2008.
43. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 13: 323–332, 2007.